<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="correction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1645773</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Correction: HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Spadotto</surname>
<given-names>Valeria</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Ripamonti</surname>
<given-names>Chiara</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2925540/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghiroldi</surname>
<given-names>Andrea</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2979430/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Galbiati</surname>
<given-names>Elisabetta</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pozzi</surname>
<given-names>Pietro</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Noberini</surname>
<given-names>Roberta</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bonaldi</surname>
<given-names>Tiziana</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steink&#xfc;hler</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fossati</surname>
<given-names>Gianluca</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/360715/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>New Drug Incubator Department, Italfarmaco Group</institution>, <addr-line>Milan</addr-line>,&#xa0;<country>Italy</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Preclinical Drug Development Department, Italfarmaco Group</institution>, <addr-line>Milan</addr-line>,&#xa0;<country>Italy</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Experimental Oncology, IEO European Institute of Oncology IRCCS</institution>, <addr-line>Milan</addr-line>,&#xa0;<country>Italy</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Oncology and Hematology-Oncology (DIPO), University of Milan</institution>, <addr-line>Milan</addr-line>,&#xa0;<country>Italy</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited and Reviewed by: S. Paul Gao, Memorial Sloan Kettering Cancer Center, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Gianluca Fossati, <email xlink:href="mailto:g.fossati@italfarmacogroup.com">g.fossati@italfarmacogroup.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1645773</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>06</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>07</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Spadotto, Ripamonti, Ghiroldi, Galbiati, Pozzi, Noberini, Bonaldi, Steink&#xfc;hler and Fossati.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Spadotto, Ripamonti, Ghiroldi, Galbiati, Pozzi, Noberini, Bonaldi, Steink&#xfc;hler and Fossati</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="Front Immunol" journal-id-type="nlm-ta" xlink:href="10.3389/fimmu.2025.1546939" ext-link-type="doi">A Correction on <article-title>HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy</article-title> By Spadotto V, Ripamonti C, Ghiroldi A, Galbiati E, Pozzi P, Noberini R, Bonaldi T, Steink&#xfc;hler C and Fossati G (2025). <italic>Front. Immunol.</italic> 16:1546939. doi:&#xa0;<object-id>10.3389/fimmu.2025.1546939</object-id>
</related-article>
<kwd-group>
<kwd>HDAC6</kwd>
<kwd>monocytes</kwd>
<kwd>immuno-checkpoints</kwd>
<kwd>TNF-&#x3b1;</kwd>
<kwd>dendritic cells</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="474"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>In the published article, there was an error in <xref ref-type="fig" rid="f6">
<bold>
<bold>Figure&#xa0;6</bold>
</bold>
</xref> as published. There was a mistake in the axes of <xref ref-type="fig" rid="f6">
<bold>
<bold>Figure&#xa0;6C</bold>
</bold>
</xref> and <xref ref-type="fig" rid="f6">
<bold>
<bold>Figure&#xa0;6D</bold>
</bold>
</xref> as published, and as a result, the list of the genes were not correct. The corrected <xref ref-type="fig" rid="f6">
<bold>
<bold>Figure&#xa0;6</bold>
</bold>
</xref> and its caption &#x201c;ITF3756 downregulates monocytes activation and differentiation markers activated by TNF-&#x3b1; and promotes a less immunosuppressive phenotype in TNF-&#x3b1; stimulated monocytes. Purified human monocytes were treated for 2h with ITF3756 (1&#x3bc;M) and then stimulated with TNF-&#x3b1; (100ng/ml) for 4h. RNAseq data obtained as described before were used for this analysis. <bold>(A)</bold> Analysis of the modulation of specific markers of monocytes-derived cell population by TNF-&#x3b1; (left panel) and by the combination of TNF-&#x3b1; and ITF3756 (right panel). Fold changes (FC) are calculated versus the unstimulated control cells or versus the TNF-&#x3b1; stimulated cells, respectively. <bold>(B&#x2013;D)</bold> Analysis of the modulation by TNF-&#x3b1; and by the combination of TNF-&#x3b1; and ITF3756 of a list of inhibitory immune checkpoints (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1546939/full#B31">31</ext-link>). Fold changes (FC) are calculated versus the unstimulated control cells in <bold>(B)</bold>, versus the TNF-&#x3b1; stimulated cells in <bold>(C)</bold> and between ITF3756 and unstimulated control cells in <bold>(D)</bold>. Significant differentially expressed genes are represented as circles, while non-significant genes are shown as triangles&#x201d; appear below.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>ITF3756 downregulates monocytes activation and differentiation markers activated by TNF-&#x3b1; and promotes a less immunosuppressive phenotype in TNF-&#x3b1; stimulated monocytes. Purified human monocytes were treated for 2h with ITF3756 (1&#x3bc;M) and then stimulated with TNF-&#x3b1; (100ng/ml) for 4h. RNAseq data obtained as described before were used for this analysis. <bold>(A)</bold> Analysis of the modulation of specific markers of monocytes-derived cell population by TNF-&#x3b1; (left panel) and by the combination of TNF-&#x3b1; and ITF3756 (right panel). Fold changes (FC) are calculated versus the unstimulated control cells or versus the TNF-&#x3b1; stimulated cells, respectively. <bold>(B&#x2013;D)</bold> Analysis of the modulation by TNF-&#x3b1; and by the combination of TNF-&#x3b1; and ITF3756 of a list of inhibitory immune checkpoints (31). Fold changes (FC) are calculated versus the unstimulated control cells in <bold>(B)</bold>, versus the TNF-&#x3b1; stimulated cells in <bold>(C)</bold> and between ITF3756 and unstimulated control cells in <bold>(D)</bold>. Significant differentially expressed genes are represented as circles, while non-significant genes are shown as triangles.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1645773-g006.tif">
<alt-text content-type="machine-generated">Four scatter plots (A, B, C, D) display log2 fold changes for gene expression under different conditions. Plots show significance and markers of various cell types, with dot sizes indicating base mean levels. Graph A includes diverse cell markers like monocytes and dendritic cells, with colors distinguishing them. Graphs B, C, and D are green, indicating different settings and focus on inhibitory immune checkpoints. Triangles and circles represent significance, with annotations provided for each shape.</alt-text>
</graphic>
</fig>
<p>The original article has been updated.</p>
</body>
<back>
<sec id="s2" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>